COVID-19
COVID-19, or Coronavirus disease 2019, is an infectious and contagious disease caused by the SARS-CoV-2 virus, first identified in Wuhan, China, in December 2019, which rapidly led to a global pandemic. Vaccines have proven effective in reducing the likelihood of contracting COVID-19 and mitigating the severity of the infection.
Health Outcomes
- Accelerated Recovery of B Cell-Mediated Respiratory Immunity
- Achieved Complete Symptom Cessation
- Asymptomatic Carrier Status
- Decreased Oxygen Saturation
- Decreased Oxygenated Hemoglobin Level
- Delayed Onset of Illness Episode
- Duration of Symptoms
- Enhanced Antibody Secretion
- Enhanced Antipathogenic Activity
- Enhanced Antiviral Response
- Enhanced Early Immune Response
- Enhanced Immune Evasion
- Enhanced Immune System
- Enhanced Innate Antiviral Immune Response
- Enhanced Innate Immune Cell Activity
- Enhanced Interferon Gamma Production
- Enhanced Interferon Production
- Enhanced Resistance to Infections
- Enhanced Respiratory Burst Activity
- Improved Airway Secretion Clearance
- Improved Anti-infection Response
- Improved Antiviral Effect
- Improved Antiviral Immune Response
- Improved COVID-19 Disease Outcomes
- Improved Chest X-Ray Finding
- Improved Clinical Protection Against Viral Challenge
- Improved Clinical Success
- Improved Defense Mechanism Recovery
- Improved Host Health
- Improved IFN-γ Levels
- Improved Immunological Biomarkers
- Improved Immunological Indices
- Improved Immunological Response
- Improved Lower Limit of Detection
- Improved Lung Barrier Function
- Improved Lung Function
- Improved Lymphocyte Count
- Improved Negative Conversion Rate
- Improved Neutrophil Function
- Improved Overall Survival During Infection
- Improved Oxygenation Index
- Improved Pathogen Clearance
- Improved Perceived Recovery
- Improved Recovery Rate
- Improved Relative Survival Rate Against Pathogen
- Improved Resistance to Viral Infections
- Improved Seroconversion
- Improved Serum Immunity
- Improved Specific Antibody Response
- Improved Survival After Viral Challenge
- Improved Survival Rate Against Infection
- Improved Survival Rate Following Infection
- Improved Symptom Resolution
- Improved Symptoms in Post-Spike Syndrome
- Improved Taste Function
- Improved Total Antibody Concentration
- Improved Vaccine-Specific Secretory IgA Levels in Saliva
- Increased Adverse Events
- Increased Antibody Response
- Increased Antibody Titer
- Increased Body Temperature
- Increased CD3+CD4+IFN-γ+ T Cell Count
- Increased CD4-CD8 Ratio
- Increased CD8 Percentage
- Increased CD8+ T Cells
- Increased Days Alive and Out of Hospital
- Increased Fever
- Increased Infection
- Increased Interferon Production
- Increased Length
- Increased Mortality
- Increased Mortality Rate
- Increased Mortality in Patients with Enterococcal Bacteremia
- Increased Nitric Oxide Level
- Increased Sepsis
- Increased Serum Interferon Gamma Levels
- Increased Specific Antibody Levels
- Increased Survival Against Pathogens
- Increased Survival Rates of Infected Hosts
- Increased Type I Interferon Production
- Induced Antigen-Specific Protective Mucosal Immune Response
- No Adverse Safety Findings
- No Antiviral Effect
- No Measurable IFN-Alpha Induction
- No Significant Effect on Small Intestinal Permeability
- Occurrence of Necrotising Pneumonia
- Protection Against Pathogen Dissemination
- Reduced Acute Kidney Injury
- Reduced Acute Respiratory Tract Infection Incidence
- Reduced Antimicrobial Use
- Reduced Appetite Changes
- Reduced BCG Phagocytic Intake
- Reduced Bloody Nasal Mucus
- Reduced CD8 Cell Percentage
- Reduced COVID-19 Immune Support Needs
- Reduced COVID-19 Symptom Duration
- Reduced Cervical Lymphadenopathy Frequency
- Reduced Circulating Monocytes
- Reduced Cold/Flu Medication Use
- Reduced Community-Acquired Infection
- Reduced Cough Duration
- Reduced Day Care Absence
- Reduced Duration of Antipyretic Therapy
- Reduced Duration of Mechanical Ventilation
- Reduced Duration of Respiratory Tract Infection Episode
- Reduced Fever
- Reduced Fever Days
- Reduced Free Triiodothyronine
- Reduced Frequency of Upper Respiratory Tract Infections
- Reduced Glutathione Loss
- Reduced Hoarseness Duration
- Reduced Hospital Length of Stay
- Reduced Hospital Mortality Rate
- Reduced Hospital Stay Duration
- Reduced Hospitalization Duration
- Reduced Household Transmission Rate
- Reduced Illness Incidence
- Reduced In-hospital Mortality
- Reduced Incidence of Infections
- Reduced Infection Incidence
- Reduced Infection Rate
- Reduced Infection Severity
- Reduced Intensive Care Unit Mortality
- Reduced Intensive Care Unit Stay
- Reduced Interleukin Level
- Reduced Interleukin-1 Level
- Reduced Length of Hospitalization
- Reduced Length of Intensive Care Unit Stay
- Reduced Length of Stay
- Reduced Lower Respiratory Infection
- Reduced Lung Tissue Damage
- Reduced Mechanical Ventilation Duration
- Reduced Morbidity
- Reduced Mortality Post-Infection
- Reduced Mortality Rate
- Reduced Mortality Rate During Pathogen Challenge
- Reduced NO Secretion Induced by LPS
- Reduced Nasal Congestion
- Reduced Need for Continuous Renal Replacement Therapy
- Reduced Need for Intubation or Ventilation
- Reduced Negative Conversion Time
- Reduced Neutrophil Extracellular Trap Formation
- Reduced Nosocomial Infection Incidence
- Reduced Parental Absenteeism from Work
- Reduced Pathogen Incidence
- Reduced Pathogen Infection
- Reduced Pathogen-Induced Weight Loss
- Reduced Pulmonary Inflammation
- Reduced Respiratory Tract Infection
- Reduced Respiratory Tract Infection Episode
- Reduced Respiratory Tract Infections
- Reduced Risk of Pathogen Dissemination
- Reduced SARS-CoV-2 Replication
- Reduced SOFA Score
- Reduced Sepsis Incidence
- Reduced Short-term Mortality
- Reduced Symptom Duration
- Reduced Th17 Cell Level
- Reduced Time to Crisis Resolution
- Reduced Upper Respiratory Tract Infection Symptom Severity
- Reduced Viral Activity
- Reduced Viral Clearance Time
- Reduced Viral Infection
- Reduced Viral Load in Epithelial Cells
- Reduced Viral Respiratory Infection
- Shortened Treatment Course
- White Blood Cell Count